MINI REVIEW article
TLR7/TLR9- and B Cell Receptor-Signaling Crosstalk: Promotion of Potentially Dangerous B Cells
- 1Department of Medicine, Division of Hematological Malignancies and Cellular Therapy, Duke Cancer Institute, Duke University Medical Center, Durham, NC, United States
- 2Department of Immunology, Duke University Medical Center, Durham, NC, United States
B cells are capable of receptor-mediated responses to foreign antigens. Recognition of microbial-derived nucleic acid (NA) by toll-like receptors (TLRs) 7 and 9 in B cells has been substantiated. Endogenous NA released from damaged or dying cells can also be immunogenic in certain contexts and can incite aberrant activation of B cells. When TLR-driven B cell receptor (BCR)-activated B cells are not properly constrained, pathologic autoantibodies are produced. It is also clear that endosomal TLR7/TLR9 can operate in conjunction with BCR. In addition to BCR signaling, a balance between TLR7 and TLR9 is pivotal in the development of B cell autoreactivity. While TLR9 is important in normal memory B cell responses through BCR, TLR9 activation has been implicated in autoantibody production. Paradoxically, TLR9 also plays known protective roles against autoimmunity by directly and indirectly inhibiting TLR7-mediated autoantibody production. Herein, we summarize literature supporting mechanisms underpinning the promotion of pathological BCR-activated B cells by TLR7 and TLR9. We focus on the literature regarding known points of TLR7/TLR9 and BCR crosstalk. Data also suggest that the degree of TLR responsiveness relies on alterations of certain intrinsic B-cell signaling molecules and is also context specific. Because allogeneic hematopoietic stem cell transplantation is a high NA and B cell-activating factor environment, we conclude that B cell studies of synergistic TLR–BCR signaling in human diseases like chronic graft-versus-host disease are warranted. Further understanding of the distinct molecular pathways mediating TLR–BCR synergy will lead to the development of therapeutic strategies in autoimmune disease states.
Toll-like receptor (TLR) responses to nucleic acids (NAs) have been extensively studied in monocytes and macrophages (1). In B cells, TLRs, such as TLR7 and TLR9, have been shown to mediate cell responses to both immunogenic NAs and NA-containing immune complexes (ICs) (2–4). Under normal conditions, B cells can respond immediately to initial microbial insults through NA recognition. B cells can also mount recall responses to previously encountered infectious agents and perpetuate life-long serological memory (5). However, when excessive cellular or tissue damage occurs and B cell responses to endogenous cellular NA are not restrained, autoantibodies and autoimmunity are promoted (6). A body of evidence has elucidated cooperative TLR7 or TLR9 (TLR7/TLR9) and B cell receptor (BCR) activation in aberrantly activated B cells. Further understanding of potential molecular synergy between BCR and TLR7/TLR9 pathways in B cells will enable development of agents that can potentially prevent autoimmune states in patients.
TLR7 and TLR9 Activation Versus Attenuation of Autoreactive B Cells
A number of murine models have been employed to substantiate the roles of TLR9 and/or TLR7 in the production of DNA-associated and RNA-associated autoantibody production, respectively (Table 1). TLR7-deficient autoimmune-prone mice display reduced or absent RNA-associated antibodies, whereas Tlr9-deficient mice have lower amounts of anti-nucleosome and anti-chromatin antibodies (7–9). A pathogenic role for TLR7 was revealed via characterization of the Y chromosome-linked autoimmune accelerating (Yaa) mouse that has known TLR7 overexpression due to gene duplication (10, 11). When Yaa are combined with systemic lupus erythematosus (SLE) mice and the Tlr9 gene knocked out, mice have increased RNA-associated antibodies, exacerbated clinical symptoms, and accelerated mortality (12). Unexpectedly, in all autoimmune-prone mouse models, including MRL/lpr, B6/lpr, Balb/c-Pristane, B6.Nba2.Yaa, B6 Yaa, and Ali5 deficient in TLR9, RNA-associated antibodies are increased, suggesting a more complex role for TLR9 in SLE (8, 9, 12–17). In fact, on an autoimmune-prone background, Tlr9 deficiency alone leads to overall increased immune activation, exacerbation of pathogenesis, and in some cases increased mortality (8, 9, 12–15). By contrast, Tlr7-deficiency in autoimmune-prone mice leads to a significant decrease in overall immune activation and disease severity (9, 14). Thus, TLR7 and TLR9 have opposing pathogenic and protective roles, respectively, in autoimmune disease.
Table 1. TLR7/TLR9 responses have substantiated roles in both autoantibody production and autoimmunity, especially in B cell receptor (BCR)-activated B cells.
Nundel et al. found that TLR9 directly constrains BCR–TLR7-dependent responses, suggesting a B-cell intrinsic protective role for TRL9 (18). By contrast, Tlr7-deficient B cells are not responsive to DNA-containing ICs and have increased death rates. Interestingly, BCR–TLR9-mediated post-proliferative cell death of B cells when TLR7 is absent can be blocked by the TNF family survival cytokine B cell-activating factor (BAFF). Nickerson et al. observed that TLR9 was associated with anti-dsDNA B cell sequestration and deletion, corroborating a protective role for TLR9 (19). The relative contributions of B cell-intrinsic TLR7 and TLR9 on autoimmunity were addressed by Jackson et al. This group generated mixed bone marrow (BM) chimeras by adoptively transferring BM from wild type, Wiskott–Aldrich syndrome (WAS) protein-deficient, Was-deficient-Tlr7-deficient, or Was-deficient-Tlr9-deficient mice with μMT BM (20:80) into lethally irradiated μMT recipient mice (20). In this chimeric WAS model, B cells were the predominant cells rendered WAS-deficient and hyperactive. Since immune dysregulation and autoimmunity was largely confined to the B cell compartment, results suggest that the TLR9 and TLR7 effects were B-cell intrinsic (20). Further studies in B cell-specific knockout models are needed to clarify any impact from the 20% myeloid cells also found in this TLR7/TLR9-deficient chimeric model (20). Together, data highlight a need to better understand the molecular mechanisms that underpin pathological or protective responses of TLR7/TLR9 responses in B cells.
TLR7– and TLR9–BCR Responses are Limited by Availability and Trafficking of NA Ligand
TLR7 and TLR9 are located in endosomal compartments and as a consequence, are usually sequestered away from NA-associated ligands. Immunogenic NA is derived from microbes or from damaged or dying cells located in the extracellular matrix (21). In both the physiological and autoimmune settings, endogenous NAs are more likely to form complexes with proteins or antibodies. As depicted in Figure 1A, TLR7/TLR9 ligands like NA-bound proteins can be brought into the B cell via several potential mechanisms. Endocytosis of NA-bound protein and diffusion of a synthetic agent (e.g., imiquimod/R848 or CpG) are known examples. Alternatively, NA or NA-ICs can be recognized and internalized by BCRs or Fc receptors and then presented to endosomal TLR7 or TLR9 for subsequent activation (6, 21). Trafficking of TLR7 and TLR9 from the endoplasmic reticulum to endosomal compartments is tightly regulated by the chaperone protein, UNC93B1 (22). The balance of TLR7:TLR9 determines downstream effector function in part because of outcompetition of TLR9 binding to UNC93B1 (23, 24).
Figure 1. TLR7/TLR9 and B cell receptor (BCR) ligands incite B cell signaling cascades. (A) Depiction of how immunogenic extracellular nucleic acid (NA) antigens are internalized to activate endosomal TLR7 and TLR9. NA antigens comprising double-stranded deoxyribonucleic acid (dsDNA) or single-stranded ribonucleic acid (ssRNA) or synthetic analog reach the endosomal compartment via any of the following potential mechanisms: (1) membrane uptake of immune complex (IC) (NA protein or antibody); (2) diffusion (synthetic compounds or oligonucleotides), or (3) BCR- or Fc receptor (FcR)-mediated internalization when either is recognized directly. Once internalized, the NA component of the IC binds the appropriate toll-like receptor (TLR) molecule, initiating dimerization and signal transduction. TLR7/TLR9 and BCR pathway stimulation leads to the activation of nuclear factors and to transcription of additional activation genes, such as mediators of proliferation and effector cytokines. Trafficking of TLR7 and TLR9 from the endoplasmic reticulum to endosomal compartments is tightly regulated by the chaperone protein, UNC93B1. (B) The major molecular activators immediately downstream of the BCR and TLR7/TLR9 and molecular points of crosstalk between the two signaling pathways. On the left-hand side, initial activation of TLR7/TLR9 by NA in the endosome leads to the recruitment and binding of MyD88 to their intracellular domains. This TLR7/TLR9 activation leads to Myddosome complex composed of MyD88, IRAK1, IRAK4, and subsequent recruitment of TNF receptor-associated factor 6 (TRAF6), each activated sequentially. Ubiquitinated TRAF6 associates with and polyubiquitinates the TAK1 complex (including proteins TAB 1 and TAB 2, not depicted). TAK1 then undergoes autophosphorylation, initiating the MAPK or NFκB pathways. These pathways can each result in the activation of important transcription factors including NFκB, AP-1, and IRFs (3, 5, and 7) that govern B cell fate. On the right-hand side, BCR ligation activates proximal kinase proteins including Lyn, Blk, Syk, and Btk. These kinases phosphorylate adaptor molecules including, BLNK, BCAP, and BANK1, which function as scaffolding proteins and allow for the many divergent pathways activated downstream of BCR including PLCγ2, MAPK, PI3K, and NFκB pathways. Molecules known to convey crosstalk between the BCR–TLR pathways upon ligation by NA-ICs include Lyn, Syk, Btk, BANK1, BCAP, TAK1, and DOCK8. The proposed mechanism of positive or negative regulation of TLR signaling is shown. Key: arrows = activation; multiple arrows = indirect activation; perpendicular lines = inhibition; broken lines = unknown in B cells because published work done on non-B cells; solid lines = protein association; gray broken arrow = contradictory regulation of TLR signaling; circled question-mark = mechanism of TLR regulation unknown. Abbreviations: Lyn, Lck/Yes-related novel protein tyrosine kinase; Blk, B-lymphoid tyrosine kinase; Syk, spleen tyrosine kinase; Btk, Bruton tyrosine kinase; BLNK, B cell linker protein; BCAP, B cell adaptor for phosphoinositide 3-kinase; BANK1, B cell scaffold protein with ankyrin repeats 1; PLCγ2, phosphoinositide-specific C phospholipase gamma 2; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; TAK1, TGFβ-activated kinase 1; MAPK, mitogen-activated kinase; MyD88, myeloid differentiation primary response gene 88; IRAK, interleukin-1 receptor-associated kinase; TRAF, TNF receptor-associated factor; IRF, interferon regulator factor.
Dual engagement of BCR and activation of TLR7/TLR9 were first shown in seminal papers by Marshak-Rothsteins’ group (25, 26). These investigators employed transgenic (Tg) mice that express rheumatoid factor (RF) AM14 BCR. AM14 BCR specifically binds with low affinity to IgG2a that is bound to endogenous or synthetic, highly purified NA. These IgG-NA ICs are “dual specific” and bind to BCR and various forms of NA (chromatin, dsNDA, RNA, SnRNP). A series of studies using this unique set of tools has now substantiated a requirement for BCR-IC internalization in TLR7/TLR9-mediated autoantibody production (25–27).
TLR7/TLR9 Activation of B Cells Relies on BCR Activation in Certain Contexts
The role of the BCR is not simply to internalize and present NA antigen. After BCR activation, both total and endosomal TLR9 levels increase, suggesting that BCR directly regulates TLR9 (28, 29) (Table 1). Several signaling molecules downstream of BCR operate in concert with TLR pathways to modulate TLR responses (30, 31). In the healthy state, dual BCR and TLR7/TLR9 engagement confer synergistic responses, including cytokine production, antibody production, and class-switch recombination (32, 33). In autoimmune disease, synergistic BCR–TLR7/TLR9 activation by NA-IC results in increased B cell proliferation and autoantibody production (25–27). For full activation of autoreactive RF-B cells, combined signals from the BCR and either TLR7/TLR9 are required (30, 34). Dual engagement of BCR and TLR9 by chromatin-IC leads to distinct functional outcomes (29). BCR activation can operate with TLR7 to attenuate peripheral B cell tolerance (35). Conversely, BCR–TLR9 synergy induces central tolerance through AID expression in autoreactive immature/T1 B cells (36). Together, data reveal a pivotal role for BCR in regulating TLR7 and TLR9 responses for maintaining the balance between normal and pathological B cell activation. A unique pattern of gene expression induced after co-stimulation with BCR and chromatin-ICs versus stimulation with TLR9 or BCR alone further suggests synergistic BCR–TLR signaling (29) Specific molecular mechanisms underpinning BCR–TLR signaling crosstalk are emerging as summarized below.
Proximal BCR-Signaling Components Important for TLR7/TLR9 Autoimmune Responses
Data reveal that BCR-proximal kinases Syk, Btk, and Lyn are involved in BCR–TLR7/TLR9 crosstalk (Table 1). The proximal BCR-signalosome molecules, Syk and Btk, have been associated with TLR7/TLR9 activation (37–39). In human B cells, Syk appears to be a positive regulator of TLR and TLR–BCR synergism, since inhibition of Syk blocks TLR responses (40, 41). The role of Btk in BCR–TLR signaling is less clear. Btk has been implicated in downstream signaling of TLRs, including TLR9 in B cells (42). Studies in the autoimmune setting revealed that Btk was dispensable for TLR7/TLR9 or BCR–TLR IC responses. In the absence of Btk, AM14-Tg B cells had diminished responses to BCR–TLR IC that was related to increased overall cell death, rather than to the level of activation of individual B cells (39). Lyn, a src kinase molecule associated with the positive and negative regulation of the BCR pathway (43) has been shown to negatively regulate TLR7/TLR9 activation (44–46). Lyn-deficient or B cell-specific Lyn-deficient mouse models had increased NA-associated autoantibodies, cytokine production (including IL-6 and IL-10), and autoimmune pathology (44–46). The exact mechanism of this negative regulatory role in TLR signaling has not been defined in B cells, although it is well established that Lyn is required to phosphorylate and activate CD22, an important negative regulator of BCR signaling (43). While the mechanistic role for Btk remains somewhat contradictory, roles for Lyn and Syk are more defined.
BCR and TLR7/TLR9 Signaling Cascades: Crosstalk and Potential Aberrant B Cell Activation
Figure 1B is a simplified depiction of the major molecular components TLR7/TLR9 and BCR signaling. As depicted on the left in Figure 1B, TLR7 and TLR9, unlike BCR, signal in a MyD88-dependent fashion. After ligand associates with TLR7 or TLR9 in the endosomal compartment, TLR monomers dimerize and recruit the adaptor protein MyD88 to the intracellular domains. MyD88 then binds the kinase interleukin-1 receptor-associated kinase (IRAK)-4, promoting its autophosphorylation. IRAK4 subsequently associates with and phosphorylates IRAK1 (47). The resultant multimeric MyD88–IRAK4–IRAK1 complex (often referred to as the “Myddosome”) is critical for downstream effector signaling. Phosphorylation of IRAKs is required for recruitment of the E3 ubiquitin ligase TNF receptor-associated factor 6 (TRAF6) to the complex (48). TRAF6, together with two other ubiquitin-conjugating enzymes (not depicted), itself becomes ubiquitinated before translocation into the cytosol where it activates transforming growth factor-beta-activated kinase 1 (TAK1) (48). TAK1 activation results in the phosphorylation and subsequent activation of MAPKs and/or NFκB. NFκB activation leads to phosphorylation of downstream transcription factors, including interferon regulatory factors (IRFs)—IRF3, IRF5, or IRF7. After phosphorylation by TRAF6, these IRFs are translocated to the nucleus where they ultimately determine cell fate (47, 49, 50). As shown on the right in Figure 1B, BCR activation incites signaling through activation of proximal BCR molecules Syk, Lyn, and Btk. When soluble antigen ligates the BCR or when BCR is cross-linked by anti-IgM surrogate antigen, several src kinases including Lyn are rapidly activated. In turn, immuno-receptor tyrosine-based activation motifs (ITAM) within the cytoplasmic domains of the CD79a/CD79b heterodimer complex of the BCR are phosphorylated by Lyn (43). Dual phosphorylation of ITAM tyrosine residues allows the association and subsequent activation of Syk tyrosine kinase (51). Syk can then associate with and activate a number of other kinases, including Btk and adaptor proteins such as B cell linker protein (BLNK) and B cell adaptor for phosphoinositide 3-kinase (BCAP) (51). Another adaptor protein, B cell scaffold protein with ankyrin repeats 1 (BANK1) is primarily activated by B-lymphoid tyrosine kinase (Blk) (52). Adaptor proteins, BANK1 and BCAP, lack kinase activity but function as scaffold proteins in the formation of macromolecular complexes that enable efficient effector signal transduction. Subsequent downstream signals include PLCγ2 activation, calcium mobilization, MAPK, NFκB pathways, and BCAP–PI3K-mediated pathways (52–54).
Improved understanding of distinct molecular mediators of BCR–TLR crosstalk in normal versus aberrant B-cell signaling is emerging. As shown in Figure 1B, BCR-proximal kinases Lyn and Syk have been specifically implicated in molecular BCR–TLR7/TLR9 crosstalk. Lyn has been shown to negatively regulate TLR activation in vivo (44–46). While not yet studied directly in B cells, the molecular mechanism may be similar to that found in dendritic cells, where Lyn directly associates with IRF5 and in doing so, inhibits the ability of TRAF6 to associate with and activate the transcription factor (55). Syk is a positive regulator of TLR signaling (40, 41). Syk activation has been associated with TRAF6 expression in B cells from patients with SLE (38). The association between Syk and TRAF6 suggests an important point of crosstalk in the context of autoimmune disease, suggesting a potential mechanism for how Syk blockade attenuates the TLR9 responses (40).
B cell adaptor proteins, BCAP and BANK1, are also potential components of BCR-endosomal TLR signaling crosstalk (Figure 1B). BCAP negatively regulates inflammatory responses mediated by TLRs 4, 7, and 9 by linking TLR–PI3K pathways (56–58). This has been shown to occur through a hidden TIR domain in the full-length BCAP protein, which allows its direct association with TLR adaptor proteins (58, 59). Recently, Halabi et al. published that BCAP binds directly with TLR adaptor proteins to facilitate PLCγ2- and PI3K-mediated depletion of the cell membrane phospholipid component of macrophages (59). Without these phospholipid substrates, the TLR adaptor proteins could not associate with the cell membrane. This potentially results in inhibition of subsequent signal transduction (59). Similar mechanisms downstream of endosomal TLR7/TLR9 may be utilized by B cells, but this requires further investigation. B cell adaptor proteins may also positively regulate TLR7/TLR9. BANK1 in B cells has been shown to augment TLR7/TLR9 signaling; however, the exact mechanism remains unknown (60, 61). Splenic B cells from Bank1-deficient mice had significantly decreased TLR9 responses mediated via a p38MAPK-dependent mechanism (61). This positive regulatory role of BANK1 was further supported in the autoimmune setting. Bank1-deficient mice crossed with B6Sle1.Yaa mice (the TLR7 overexpressing autoimmune model) resulted in reduced IgG production (importantly the pathogenic-associated IgG2a isotype) and reduced IL-6 and BAFF serum levels (60). This was confirmed to be B-cell intrinsic, as ex vivo TLR7 responses were impaired (60). Thus, early evidence has identified important roles for BCR adaptor proteins in aberrant B cell responses to TLR in autoimmune disease.
Two other proteins have been implicated in BCR–TLR crosstalk. TAK1 has been suggested to be at the exact point of synergism between the BCR–TLR9 pathways (62). Synergistic BCR–TLR9 activation was abrogated when TAK1 was inhibited and silenced (62). Jabara et al. identified the adaptor dedicator of cytokinesis-8 (DOCK8) as the link between TLR9 and STAT3 activation in B cells (63). This link was dependent upon the BCR-signaling components Lyn and Syk (63). CpG activation of TLR9 induced migration of the preexisting complex consisting of MyD88, DOCK8, and Pyk2 to the cytoplasmic tails of TLR9. This association induced phosphorylation of DOCK8 by Pyk2 and allowed Lyn to bind to DOCK8. Binding of DOCK8 to Lyn leads to subsequent activation of Syk, and activation of STAT3, resulting in gene expression important for long-lived memory B cell survival and antibody production (63). Importantly, DOCK8 was not required for initial BCR signaling. This suggests a pivotal role for the integration of DOCK8 and TLR–BCR signaling cascades in BCR activation by low affinity antigen, although studies examining simultaneous BCR and TLR9 activation are required to address this. Thus, in the physiological context NA-ICs when low affinity BCR is activated before NA is presented to TLR9, DOCK8, Syk, and Lyn may all play even more significant roles in integration of BCR–TLR9 signaling.
Future Studies: TLR–BCR-Mediated Autoimmunity in Humans
We now know there are a number of molecular links between BCR and TLR7/TLR9 signaling. Further studies are required to determine distinct pathologic signaling pathways so that agents can be used to block aberrant TLR/BCR signaling in patients. Future studies should address mechanisms that restrain potentially dangerous responses to antigen in autoimmune-provoking environments. To do this, more physiological research tools are required to further define mechanisms of TLR–BCR signaling, particularly for studies of human B cells. Many studies use anti-IgM surrogate antigen for the BCR-activation component, which does not precisely recapitulate the more physiological setting of BCR–TLR activation by ICs that requires internalization. Additional technical challenges need to be addressed. Potentially pathogenic B cells are already in an activated state, hampering the ability to stimulate and delineate meaningful mechanistic studies ex vivo without inducing cell death. Gene knockdown is also challenging in primary disease-state B cells. Until these technical and logistical barriers are overcome, studies of synergistic BCR–TLR signal transduction in the physiological setting in human B cells remain challenging.
Understanding B-cell intrinsic BCR–TLR signaling and activation in the context of human disease will also require investigation of extrinsic factors involved in the promotion of autoreactive B cells. BAFF plays a pivotal role in B cell development and the maintenance of B cell homeostasis (64). Elevated BAFF levels have been implicated in breaking B cell tolerance in systemic autoimmune diseases including SLE and Sjorgren’s syndrome (SS) (65). Elevated serum BAFF levels have been correlated with circulating autoantibodies, disease progression, and anti-dsDNA antibodies in SLE patients (66, 67) and with autoantibody levels in SS patients (68). One mechanism by which BAFF breaks this tolerance in a lupus-like disease model has been shown to be TLR-dependent (69). Data suggest a model whereby excess BAFF expands autoreactive B cells, and BAFF signals directly promote TLR activation and internalization of dsDNA or NA-IC autoreactive BCRs. BAFF also increases TLR7/TLR9 expression, and TLR7/TLR9 signaling promotes BAFF receptor expression, thus providing a positive feedback loop (69). Further study will elucidate how the extrinsic factor BAFF dysregulates intrinsic BCR–TLR B cell signals and promotes aberrant B cell activation and pathogenesis.
Implications for a Disease that Develops in an Autoimmune-Provoking Environment: Allogeneic Hematopoietic Stem Cell Transplantation (HCT)
Current evidence as summarized above compels examination of aberrant B cells in patients with autoimmune pathology. This includes patients who develop chronic graft-versus-host disease (cGVHD) that develops after HCT. cGVHD is a B-cell mediated autoimmune disease-like state that is unacceptably debilitating and difficult to treat. Persistently altered B cell homeostasis in patients with cGVHD is potentially perpetuated by global B cell depletion strategies (70–72). In cGVHD, intrinsic abnormalities in the proximal BCR machinery of B cells are being defined. Thus, we and others are interested in developing ways to target only B cells from patients with cGVHD that are hyperactivated and primed for survival in vivo via BAFF- and BCR-associated pathways (73). Based on murine and human studies that demonstrated a role for BCR-activated B cells in the pathophysiology of cGVHD (74, 75), the novel application of signaling pathway inhibitors is being tested in clinical trials.
After HCT, B cells are recovering in an NA and alloantigen (76) rich environment that may promote pathological B cells. Circulating monocytes in cGVHD patients upregulate gene pathways involved in innate cellular damage responses (77). Some of these genes include TLR7, BAFF and Type 1 interferons. No definitive examination of TLR7/TLR9 in cGVHD has yet been performed, but studies suggest that there is a muted signaling response to TLR9 agonists by plasmablast-like cells that normally regulate immune responses via the production of cytokines including IL-10 (78). We conclude that studies of cGVHD addressing TLR9 and TLR7 signaling of BCR-activated B cells after HCT are warranted. Such studies will inevitably lead to further understanding of human B cell tolerance and will likely compel the expanded use of targeted therapeutic agents in patients.
SS and AS both researched the topic, wrote and edited the manuscript, and made the table and figure for this manuscript.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The authors thank Dr. Jonathan Poe, PhD for editing the manuscript.
National Institutes of Health grant R01 HL 129061 (NHLBI) was awarded to SS.
4. Jimenez-Dalmaroni MJ, Gerswhin ME, Adamopoulos IE. The critical role of toll-like receptors – from microbial recognition to autoimmunity: a comprehensive review. Autoimmun Rev (2016) 15(1):1–8. doi:10.1016/j.autrev.2015.08.009
6. Rifkin IR, Leadbetter EA, Busconi L, Viglianti G, Marshak-Rothstein A. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev (2005) 204(1):27–42. doi:10.1111/j.0105-2896.2005.00239.x
7. Berland R, Fernandez L, Kari E, Han JH, Lomakin I, Akira S, et al. Toll-like receptor 7-dependent loss of B cell tolerance in pathogenic autoantibody knockin mice. Immunity (2006) 25(3):429–40. doi:10.1016/j.immuni.2006.07.014
8. Christensen SR, Kashgarian M, Alexopoulou L, Flavell RA, Akira S, Shlomchik MJ. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med (2005) 202(2):321–31. doi:10.1084/jem.20050338
9. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity (2006) 25(3):417–28. doi:10.1016/j.immuni.2006.07.013
10. Fairhurst A-M, Hwang S-h, Wang A, Tian X-H, Boudreaux C, Zhou XJ, et al. Yaa-autoimmune phenotypes are conferred by an overexpression of TLR7. Eur J Immunol (2008) 38(7):1971–8. doi:10.1002/eji.200838138
11. Pisitkun P, Deane JA, Difilippantonio MJ, Tarasenko T, Satterthwaite AB, Bolland S. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science (2006) 312(5780):1669–72. doi:10.1126/science.1124978
12. Santiago-Raber M-L, Dunand-Sauthier I, Wu T, Li Q-Z, Uematsu S, Akira S, et al. Critical role of TLR7 in the acceleration of systemic lupus erythematosus in TLR9-deficient mice. J Autoimmun (2010) 34(4):339–48. doi:10.1016/j.jaut.2009.11.001
13. Lartigue A, Courville P, Auquit I, Francois A, Arnoult C, Tron F, et al. Role of TLR9 in anti-nucleosome and anti-DNA antibody production in lpr mutation-induced murine lupus. J Immunol (2006) 177(2):1349–54. doi:10.4049/jimmunol.177.2.1349
14. Nickerson KM, Christensen SR, Shupe J, Kashgarian M, Kim D, Elkon K, et al. TLR9 regulates TLR7- and MyD88-dependent autoantibody production and disease in a murine model of lupus. J Immunol (2010) 184(4):1840–8. doi:10.4049/jimmunol.0902592
15. Bossaller L, Christ A, Pelka K, Nundel K, Chiang PI, Pang C, et al. TLR9 deficiency leads to accelerated renal disease and myeloid lineage abnormalities in pristane-induced murine lupus. J Immunol (2016) 197(4):1044–53. doi:10.4049/jimmunol.1501943
16. Yu P, Wellmann U, Kunder S, Quintanilla-Martinez L, Jennen L, Dear N, et al. Toll-like receptor 9-independent aggravation of glomerulonephritis in a novel model of SLE. Int Immunol (2006) 18(8):1211–9. doi:10.1093/intimm/dxl067
18. Nundel K, Green NM, Shaffer AL, Moody KL, Busto P, Eilat D, et al. Cell-intrinsic expression of TLR9 in autoreactive B cells constrains BCR/TLR7-dependent responses. J Immunol (2015) 194(6):2504–12. doi:10.4049/jimmunol.1402425
19. Nickerson KM, Christensen SR, Cullen JL, Meng W, Luning Prak ET, Shlomchik MJ. TLR9 promotes tolerance by restricting survival of anergic anti-DNA B cells, yet is also required for their activation. J Immunol (2013) 190(4):1447–56. doi:10.4049/jimmunol.1202115
20. Jackson SW, Scharping NE, Kolhatkar NS, Khim S, Schwartz MA, Li Q-Z, et al. Opposing impact of B cell-intrinsic TLR7 and TLR9 signals on autoantibody repertoire and systemic inflammation. J Immunol (2014) 192(10):4525–32. doi:10.4049/jimmunol.1400098
23. Fukui R, Saitoh S, Kanno A, Onji M, Shibata T, Ito A, et al. Unc93B1 restricts systemic lethal inflammation by orchestrating toll-like receptor 7 and 9 trafficking. Immunity (2011) 35(1):69–81. doi:10.1016/j.immuni.2011.05.010
24. Fukui R, Saitoh S, Matsumoto F, Kozuka-Hata H, Oyama M, Tabeta K, et al. Unc93B1 biases toll-like receptor responses to nucleic acid in dendritic cells toward DNA- but against RNA-sensing. J Exp Med (2009) 206(6):1339–50. doi:10.1084/jem.20082316
25. Lau CM, Broughton C, Tabor AS, Akira S, Flavell RA, Mamula MJ, et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/toll-like receptor 7 engagement. J Exp Med (2005) 202(9):1171–7. doi:10.1084/jem.20050630
26. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and toll-like receptors. Nature (2002) 416(6881):603–7. doi:10.1038/416603a
28. Chaturvedi A, Dorward D, Pierce SK. The B cell receptor governs the subcellular location of toll-like receptor 9 leading to hyperresponses to DNA-containing antigens. Immunity (2008) 28(6):799–809. doi:10.1016/j.immuni.2008.03.019
29. Busconi L, Bauer JW, Tumang JR, Laws A, Perkins-Mesires K, Tabor AS, et al. Functional outcome of B cell activation by chromatin immune complex engagement of the B cell receptor and TLR9. J Immunol (2007) 179(11):7397–405. doi:10.4049/jimmunol.179.11.7397
32. Pone EJ, Zhang J, Mai T, White CA, Li G, Sakakura JK, et al. BCR-signalling synergizes with TLR-signalling for induction of AID and immunoglobulin class-switching through the non-canonical NF-kappaB pathway. Nat Commun (2012) 3:767. doi:10.1038/ncomms1769
36. Kuraoka M, Snowden PB, Nojima T, Verkoczy L, Haynes BF, Kitamura D, et al. BCR and endosomal TLR signals synergize to increase AID expression and establish central B cell tolerance. Cell Rep (2017) 18(7):1627–35. doi:10.1016/j.celrep.2017.01.050
38. Iwata S, Yamaoka K, Niiro H, Jabbarzadeh-Tabrizi S, Wang S-P, Kondo M, et al. Increased Syk phosphorylation leads to overexpression of TRAF6 in peripheral B cells of patients with systemic lupus erythematosus. Lupus (2015) 24(7):695–704. doi:10.1177/0961203314560424
39. Nundel K, Busto P, Debatis M, Marshak-Rothstein A. The role of Bruton’s tyrosine kinase in the development and BCR/TLR-dependent activation of AM14 rheumatoid factor B cells. J Leukoc Biol (2013) 94(5):865–75. doi:10.1189/jlb.0313126
40. Kremlitzka M, Mácsik-Valent B, Erdei A. Syk is indispensable for CpG-induced activation and differentiation of human B cells. Cell Mol Life Sci (2015) 72(11):2223–36. doi:10.1007/s00018-014-1806-x
41. Iwata S, Yamaoka K, Niiro H, Nakano K, Wang SP, Akashi K, et al. Amplification of toll-like receptor-mediated signaling through spleen tyrosine kinase in human B-cell activation. J Allergy Clin Immunol (2012) 129(6):1594–601.e2. doi:10.1016/j.jaci.2012.03.014
42. Lee KG, Xu S, Wong ET, Tergaonkar V, Lam KP. Bruton’s tyrosine kinase separately regulates NFkappaB p65RelA activation and cytokine interleukin (IL)-10/IL-12 production in TLR9-stimulated B cells. J Biol Chem (2008) 283(17):11189–98. doi:10.1074/jbc.M708516200
44. Hua Z, Gross AJ, Lamagna C, Ramos-Hernández N, Scapini P, Ji M, et al. Requirement for MyD88 signaling in B cells and dendritic cells for germinal center anti-nuclear antibody production in Lyn-deficient mice. J Immunol (2014) 192(3):875–85. doi:10.4049/jimmunol.1300683
46. Nishizumi H, Taniuchi I, Yamanashi Y, Kitamura D, Ilic D, Mori S, et al. Impaired proliferation of peripheral B cells and indication of autoimmune disease in Lyn-deficient mice. Immunity (1995) 3(5):549–60. doi:10.1016/1074-7613(95)90126-4
48. Qian Y, Commane M, Ninomiya-Tsuji J, Matsumoto K, Li X. IRAK-mediated translocation of TRAF6 and TAB 2 in the interleukin-1-induced activation of NFκB. J Biol Chem (2001) 276(45):41661–7. doi:10.1074/jbc.M102262200
49. Sato S, Sanjo H, Takeda K, Ninomiya-Tsuji J, Yamamoto M, Kawai T, et al. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol (2005) 6(11):1087–95. doi:10.1038/ni1255
52. Bernal-Quirós M, Wu Y-Y, Alarcón-Riquelme ME, Castillejo-López C. BANK1 and BLK act through phospholipase C gamma 2 in B-cell signaling. PLoS One (2013) 8(3):e59842. doi:10.1371/journal.pone.0059842
54. Okada T, Maeda A, Iwamatsu A, Gotoh K, Kurosaki T. BCAP: the tyrosine kinase substrate that connects B cell receptor to phosphoinositide 3-kinase activation. Immunity (2000) 13(6):817–27. doi:10.1016/S1074-7613(00)00079-0
55. Ban T, Sato GR, Nishiyama A, Akiyama A, Takasuna M, Umehara M, et al. Lyn kinase suppresses the transcriptional activity of IRF5 in the TLR-MyD88 pathway to restrain the development of autoimmunity. Immunity (2016) 45(2):319–32. doi:10.1016/j.immuni.2016.07.015
56. Matsumura T, Oyama M, Kozuka-Hata H, Ishikawa K, Inoue T, Muta T, et al. Identification of BCAP-L as a negative regulator of the TLR signaling-induced production of IL-6 and IL-10 in macrophages by tyrosine phosphoproteomics. Biochem Biophys Res Commun (2010) 400(2):265–70. doi:10.1016/j.bbrc.2010.08.055
57. Ni M, MacFarlane AW, Toft M, Lowell CA, Campbell KS, Hamerman JA. B-cell adaptor for PI3K (BCAP) negatively regulates toll-like receptor signaling through activation of PI3K. Proc Natl Acad Sci U S A (2012) 109(1):267–72. doi:10.1073/pnas.1111957108
58. Troutman TD, Hu W, Fulenchek S, Yamazaki T, Kurosaki T, Bazan JF, et al. Role for B-cell adapter for PI3K (BCAP) as a signaling adapter linking toll-like receptors (TLRs) to serine/threonine kinases PI3K/Akt. Proc Natl Acad Sci U S A (2012) 109(1):273–8. doi:10.1073/pnas.1118579109
59. Halabi S, Sekine E, Verstak B, Gay NJ, Moncrieffe MC. Structure of the toll/interleukin-1 receptor (TIR) domain of the B-cell adaptor that links phosphoinositide metabolism with the negative regulation of the toll-like receptor (TLR) signalosome. J Biol Chem (2017) 292(2):652–60. doi:10.1074/jbc.M116.761528
60. Wu YY, Kumar R, Iida R, Bagavant H, Alarcon-Riquelme ME. BANK1 regulates IgG production in a lupus model by controlling TLR7-dependent STAT1 activation. PLoS One (2016) 11(5):e0156302. doi:10.1371/journal.pone.0156302
61. Wu Y-Y, Kumar R, Haque MS, Castillejo-López C, Alarcón-Riquelme ME. BANK1 controls CpG-induced IL-6 secretion via a p38 and MNK1/2/eIF4E translation initiation pathway. J Immunol (2013) 191(12):6110–6. doi:10.4049/jimmunol.1301203
62. Szili D, Banko Z, Toth EA, Nagy G, Rojkovich B, Gati T, et al. TGFbeta activated kinase 1 (TAK1) at the crossroad of B cell receptor and toll-like receptor 9 signaling pathways in human B cells. PLoS One (2014) 9(5):e96381. doi:10.1371/journal.pone.0096381
63. Jabara HH, McDonald DR, Janssen E, Massaad MJ, Ramesh N, Borzutzky A, et al. DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activation. Nat Immunol (2012) 13(6):612–20. doi:10.1038/ni.2305
66. Chu VT, Enghard P, Schurer S, Steinhauser G, Rudolph B, Riemekasten G, et al. Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus. Arthritis Rheum (2009) 60:2083–93. doi:10.1002/art.24628
67. Zollars E, Bienkowska J, Czerkowicz J, Allaire N, Ranger AM, Magder L, et al. BAFF (B cell activating factor) transcript level in peripheral blood of patients with SLE is associated with same-day disease activity as well as global activity over the next year. Lupus Sci Med (2015) 2:e000063. doi:10.1136/lupus-2014-000063
68. Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren’s syndrome. Ann Rheum Dis (2003) 62(2):168–71. doi:10.1136/ard.62.2.168
69. Groom JR, Fletcher CA, Walters SN, Grey ST, Watt SV, Sweet MJ, et al. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med (2007) 204(8):1959–71. doi:10.1084/jem.20062567
71. Sarantopoulos S, Stevenson KE, Kim HT, Cutler CS, Bhuiya NS, Schowalter M, et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood (2009) 113(16):3865–74. doi:10.1182/blood-2008-09-177840
72. Sarantopoulos S, Stevenson KE, Kim HT, Washel WS, Bhuiya NS, Cutler CS, et al. Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. Blood (2011) 117(7):2275–83. doi:10.1182/blood-2010-10-307819
73. Allen JL, Fore MS, Wooten J, Roehrs PA, Bhuiya NS, Hoffert T, et al. B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. Blood (2012) 120(12):2529–36. doi:10.1182/blood-2012-06-438911
74. Allen JL, Tata PV, Fore MS, Wooten J, Rudra S, Deal AM, et al. Increased BCR responsiveness in B cells from patients with chronic GVHD. Blood (2014) 123(13):2108–15. doi:10.1182/blood-2013-10-533562
75. Flynn R, Allen JL, Luznik L, MacDonald KP, Paz K, Alexander KA, et al. Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. Blood (2015) 125(26):4085–94. doi:10.1182/blood-2014-08-595470
77. Hakim FT, Memon S, Jin P, Imanguli MM, Wang H, Rehman N, et al. Upregulation of IFN-inducible and damage-response pathways in chronic graft-versus-host disease. J Immunol (2016) 197(9):3490–503. doi:10.4049/jimmunol.1601054
Keywords: B cell signaling, TLR9, TLR7, chronic graft-versus-host disease, allogeneic hematopoietic stem cell transplantation, B cell receptor, autoantibody production, B cell biology
Citation: Suthers AN and Sarantopoulos S (2017) TLR7/TLR9- and B Cell Receptor-Signaling Crosstalk: Promotion of Potentially Dangerous B Cells. Front. Immunol. 8:775. doi: 10.3389/fimmu.2017.00775
Received: 21 April 2017; Accepted: 19 June 2017;
Published: 13 July 2017
Edited by:Sophie Paczesny, Indiana University School of Medicine, United States
Reviewed by:Gaetan Jego, Université de Bourgogne, France
Ann M. Rothstein, University of Massachusetts Medical School, United States
Copyright: © 2017 Suthers and Sarantopoulos. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Stefanie Sarantopoulos, firstname.lastname@example.org